GDT201 / Century Therap - LARVOL DELTA

Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors (GlobeNewswire) - "Immunocore Holdings plc...and Gadeta B.V...pioneering the development of gamma delta (γδ) TCR-based immunotherapies for solid tumors, announced today that they will collaborate on the first γδ ImmTAC^® for solid tumors, including colorectal cancer....Pre-clinical data for GDT201 show promising results across a wide range of colorectal cancer cell lines and the product will be evaluated in a Phase 1 trial for a range of solid tumor indications, slated to start in H2 2023. GDT201 remains fully owned by Gadeta....Under the terms of the agreement, Immunocore and Gadeta will collaborate on ‘201 γδ-TCR target discovery, and Immunocore will have the option to develop ImmTAC therapies derived from the ‘201 TCR as part of the research collaboration."

Licensing / partnership • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Gadeta Appoints Scientific Advisory Board and Provides Business Update (PRNewswire) - "Gadeta expects to progress two solid tumor cell therapy programs towards the clinic in 2023. Its first program, GDT002, is based on a γ9δ2 TCR that targets a protein broadly expressed in both hematological as well as solid tumors.... Gadeta will now focus the clinical development of GDT002 in solid tumors and already has an open IND. The second program, GDT201, comprises a non-δ2 TCR targeting a surface protein shown to be modified in a variety of solid tumors....GDT201 will be evaluated in a phase I trial for select solid tumor indications, slated to start in H2 2023....Gadeta continues to scale up its NOVA γδ TCR discovery platform to expand its portfolio of proprietary tumor specific γδ TCRs....Gadeta will also broaden the application of γδ TCRs with other biological formats to leverage the unique tumor targeting properties of γδ TCRs."

New P1 trial • Pipeline update • Hematological Malignancies • Oncology • Solid Tumor